TTY Biopharm Company Limited (4105.TWO) Stock
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments.
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Ownership
About TTY Biopharm Company Limited
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers oncology drugs for the treatment of anticancer and adjunctive therapies under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Yondelis, Pemazyre, Pulmivex, Xpovio, Minjuvi, and Fustron names. The company also provides anti-infective drugs and anesthetics to treat second-line antimicrobial agents, influenza, and anesthetics under the Brosym, Bobimixyn, Colimycin, Cubicin, Lipo-AB, Flusine, Maxtam, Metacin, Flucelvax, Fluad, and Byfavo names; and healthcare products for the treatment of gastrointestinal health, bone health, and metabolic regulation under the Algitab, Alginos, Bio-Cal Plus, Sulfin names. In addition, it offers contract development and manufacturing (CDMO) services. The company was incorporated in 1960 and is headquartered in Taipei, Taiwan.
TTY Biopharm Company Limited (4105.TWO) stock trades at $80.60 with a market capitalization of $20.04B. The stock is valued at a price-to-earnings (P/E) ratio of 11.58, price-to-book of 2.88, price-to-sales of 3.01. Over the past 52 weeks the stock has ranged between $71.60 and $87.00, and currently trades 7.4% below its 52-week high. It pays a dividend yielding 5.54%.
On profitability, TTY Biopharm Company Limited generates a return on equity (ROE) of 25.11%, above the typical market range of roughly 12-15%, an operating margin of 29.49%, a net profit margin of 26.04%.
The balance sheet shows a debt-to-equity ratio of 0.27 (debt below half of shareholders' equity), a current ratio of 2.13.
4105.TWO has an average daily trading volume of 642,933 shares, a beta of 0.12 (historically less volatile than the overall market), 0.25B shares outstanding.
Official website: www.tty.com.tw
TTY Biopharm Company Limited (4105.TWO) — frequently asked questions
What is TTY Biopharm Company Limited (4105.TWO) stock price today?
TTY Biopharm Company Limited (4105.TWO) is currently trading at $80.60, down 0.74% today.
What is 4105.TWO P/E ratio?
TTY Biopharm Company Limited's P/E ratio is 11.58. This is below the typical market average of roughly 18-22x. A low P/E can reflect a lower valuation, slower expected growth, or both.
What is 4105.TWO return on equity (ROE)?
TTY Biopharm Company Limited's return on equity (ROE) is 25.11%. ROE measures net income relative to shareholders' equity. This is above the typical market range of roughly 12-15%.
What is TTY Biopharm Company Limited's market cap?
TTY Biopharm Company Limited has a market capitalization of $20.04B.
Does 4105.TWO pay a dividend?
Yes. TTY Biopharm Company Limited currently yields 5.54%. Yield moves with the share price, so it changes daily even when the payment does not.
How much debt does 4105.TWO carry?
TTY Biopharm Company Limited has a debt-to-equity ratio of 0.27. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is 4105.TWO's profit margin?
TTY Biopharm Company Limited reports a net profit margin of 26.04% — the share of revenue left after every cost, including tax and interest.
What sector is 4105.TWO in?
TTY Biopharm Company Limited is classified under Healthcare, in the Drug Manufacturers - Specialty & Generic industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is 4105.TWO listed on?
TTY Biopharm Company Limited trades on TWO under the ticker 4105.TWO.
What is 4105.TWO's 52-week range?
Over the last year TTY Biopharm Company Limited has traded between $71.60 and $87.00.
Related Healthcare Stocks
Popular Stocks
Screens 4105.TWO currently matches
On the figures above, TTY Biopharm Company Limited passes the filters for 22 of our ready-made screens, among them Low PE Stocks, Cheap Stocks To Buy Now, Undervalued Large Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.